AnaPath Research’s COVID-19 Pandemic Business Continuity Plan
AnaPath Research is actively monitoring the coronavirus (COVID-19) situation and its impact in Spain.
Despite the difficult times consequent to the pandemic, at AnaPath Research we remain committed to supporting our clients uninterruptedly while protecting our employees. Our planning and preparedness activities and our actions are aligned to the level of threat, the level of impact and potential for escalation.
Our Business Continuity Plan includes, but is not limited to, the following…
What’s new at AnaPath Research?
- Our team is growing
Since the company’s inception in November 2019, we have incorporated 20 colleagues to our team. Our first priority was to strengthen our key areas, such as Animal House, Pathology, General Toxicology and Bioanalysis. Now we continue to seek new talent to complement our team.
- First authorities’ audit
On 27 and 28 February, we were delighted to welcome representatives from ENAC, Spanish regulatory body, to our facilities to renew our GLP certificate for chemical, phytosanitary and agrochemical products. We are proud to announce that there were no major findings.
- Renewed animal protocols
Our Toxicology Department, Animal Welfare Officer and Animal Welfare Body reviewed and updated research projects in rodent and non-rodent species, which were approved by the Spanish authorities. We are now ready to start new studies!
- AnaPath group harmonization
The AnaPath Research Pathology team visited AnaPath Services in Switzerland launching a close cooperation to promote cross-training and harmonization between sites, fluent communication, procedure exchange and process optimization, allowing us to work as one company.
- The Bioanalysis team rocks!
The AnaPath Research Bioanalysis team signed the first contracts as early as December exponentially increasing its activity in small molecule bioanalysis. The Dose Formulation Analysis and Immunology and Molecular Biology teams are also ready to start new studies right away.
- First sponsor visits and audits
In Q1, we received several Sponsor visits and audits and are proud to announce that there were no major findings. You are more than welcome to our facilities to see how the new procedures and improvements are being implemented.
- AAALAC update
AnaPath Group wants to excel both at study quality and animal welfare. We are committed to the 3Rs: replacing animal research with alternatives, reducing the number of animals used and refining experiments to minimize harm and discomfort to the animals. We are proud of our animal care program and since October 2016 we are an AAALAC accredited organization. We are currently preparing for the next AAALAC visit scheduled for Q3.
- Ascentos LIMS validation update
Our team is focused on going live with the new LIMS platform with the aim of covering all our preclinical business. Ascentos™ comes with a comprehensive set of modules that include Pharmacy Formulations (a module fully integrated into Ascentos), Toxicology, Clinical Pathology, Developmental and Reproductive Toxicology and Pathology. The LIMS platform will allow us to comply with data integrity and accuracy as the system hosting and validation by PDS Systems is 100% GLP certified by the regulatory authorities.
- Improving facilities
A new autoclave was installed in the rodent facility. The past months have also seen upgrades in the electric infrastructure and improvements in the lighting system.
- Coronavirus outbreak – business continuity and solidarity
Despite the difficult times consequent to the coronavirus pandemic, at AnaPath Research we remain committed to supporting our clients uninterruptedly while protecting our employees.
AnaPath Research is committed to science and health care and has donated PPE (personal protection equipment) to local hospitals.
More importantly, we are committed to fighting the COVID-19 global pandemic. At AnaPath, we are willing to put all our staff, bioanalysis equipment, toxicology experience and animal house facilities at your disposal, to collaborate in all initiatives that can help validate new vaccines, drugs, medical devices and other projects to beat the COVID outbreak. If you are interested in a collaboration, please contact email@example.com and firstname.lastname@example.org.
AnaPath Services acquires Envigo CRS S.A.U. in Barcelona to provide full
services in non-clinical safety assessment for chemical and pharmaceutical industries English.
NEWS PROVIDED BY
AnaPath Services GmbH
Nov 21, 2019, 04:32 ET
GENEVA, Nov. 21, 2019 /PRNewswire/ — AnaPath Services GmbH, the Swiss CRO specialized in histopathology, has acquired legacy Envigo CRS S.A.U. a CRO for non-clinical safety assessment on November 5th , 2019.
With this step Envigo CRS was renamed to AnaPath Research S.A.U.
Furthermore Jorge Zapatero Lorenzo was appointed the general manager of AnaPath Research. Mr Zapatero has been with the company from 1986 until 2014 in roles of increasing responsibility including general manager. This merger represents a back integration as both companies worked previously together within RCC / Harlan Laboratories Spain and Switzerland. After separating due to a buyer of Harlan in 2013, AnaPath developed into a globally recognized expert CRO in histopathology and toxicology.
Common history, personal relationship and shared values will make a quick start and integration as one CRO possible; after implementation of technical upgrades, GLP in vivo studies start January 2020. This merger enhances AnaPath’s capabilities and warranties a quick and clean performance of complete safety assessment packages under one roof. The basis for this statement is given by thorough knowledge about each others skills, previously joint training periods, and organization and performance of study packages. AnaPath Services is well known for its high level scientic approach serving clients with strategies and solutions to overcome developmental hurdles. The merger enables AnaPath to convert its understanding of toxicology into immediate progression of critical milestones within Research & Development.
SOURCE AnaPath Services GmbH